Clinical Trials Directory

Trials / Completed

CompletedNCT00774163

Safety of Lactobacillus Reuteri in Healthy Volunteers

Phase 1: Safety of Lactobacillus Reuteri in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
45 (actual)
Sponsor
Tulane University School of Medicine · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This is a phase one study to assess the safety of daily dosing of Lactobacillus reuteri in healthy adults in Peru. It is conducted as a preliminary study in support of a clinical trial to assess safety and efficacy of Lactobacillus reuteri versus placebo for treatment of pediatric diarrhea in Peru.

Detailed description

This is a phase I blinded randomized study of the safety and tolerability of Lactobacillus reuteri DSM 17938 given daily for a period of five consecutive days. Upon enrollment subjects will be randomized to one of two treatment groups in a ratio of treatment to placebo of 2:1. Subjects will be randomized to receive either: A. Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730). B. Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).

Conditions

Interventions

TypeNameDescription
BIOLOGICALLactobacillus reuteriLactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
OTHERPlacebo5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period

Timeline

Start date
2010-02-01
Primary completion
2010-06-01
Completion
2010-10-01
First posted
2008-10-17
Last updated
2016-12-19
Results posted
2013-07-12

Locations

1 site across 1 country: Peru

Source: ClinicalTrials.gov record NCT00774163. Inclusion in this directory is not an endorsement.